Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PER2 | O15055 | 2/20 | 0.45 |
| ▸ | CRY1 | Q16526 | 2/20 | 0.45 |
| ▸ | CRY2 | Q49AN0 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 7/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.33 |
| ▸ | RORA | P35398 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.33 |
| ▸ | RORB | Q92753 | 1/20 | 0.33 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.33 |
| ▸ | MMP3 | P08254 | 2/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2288891 | 0.81 | TAS2R14 (0.43) | PER2CRY1CRY2LMNATAS2R14 | |
| SCHEMBL13309413 | 0.79 | PER2 (0.38) | PER2CRY1CRY2LMNATAS2R14 | |
| SCHEMBL21009518 | 0.79 | PER2 (0.35) | PER2CRY1CRY2LMNATAS2R14 | |
| SCHEMBL24894413 | 0.79 | TAS2R14 (0.39) | PER2CRY1CRY2LMNATAS2R14 | |
| SCHEMBL15139521 | 0.78 | L3MBTL1 (0.35) | PER2CRY1CRY2LMNAALDH1A1 | |
| SCHEMBL23613031 | 0.78 | CRY1 (0.42) | PER2CRY1CRY2LMNATAS2R14 | |
| SCHEMBL12339283 | 0.76 | PER2 (0.36) | PER2CRY1CRY2LMNATAS2R14 | |
| SCHEMBL12410297 | 0.76 | MMP3 (0.40) | PER2CRY1CRY2LMNATAS2R14 | |
| SCHEMBL14899179 | 0.75 | PER2 (0.33) | PER2CRY1CRY2LMNA | |
| SCHEMBL12376684 | 0.75 | MMP3 (0.39) | PER2CRY1CRY2LMNATAS2R14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9963458-B2 | Indole and indoline-type piperidine compounds and uses thereof | PURDUE PHARMA L.P. (US) | 2018-05-08 | — | — | US | disclosed |
| US-9598447-B2 | Phosphorus-substituted quinoxaline-type piperidine compounds and uses thereof | PURDUE PHARMA L.P. (US) | 2017-03-21 | — | — | US | disclosed |
| US-9527840-B2 | Substituted-quinoxaline-type piperidine compounds and the uses thereof | PURDUE PHARMA L.P. (US) | 2016-12-27 | — | — | US | disclosed |
| US-20160159785-A1 | SUBSTITUTED-QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA L.P. | 2016-06-09 | — | — | US | disclosed |
| US-9290488-B2 | Azetidine-substituted quinoxalines as opioid receptor like-1 modulators | PURDUE PHARMA L.P. (US) | 2016-03-22 | — | — | US | disclosed |
| US-9278967-B2 | Substituted-quinoxaline-type piperidine compounds and the uses thereof | PURDUE PHARMA L.P. (US) | 2016-03-08 | — | — | US | disclosed |
| US-20150315201-A1 | INDOLE AND INDOLINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | PURDUE PHARMA L.P. | 2015-11-05 | — | — | US | disclosed |
| US-9085561-B2 | Cyclic urea- or lactam-substituted quinoxaline-type piperidines as ORL-1 modulators | PURDUE PHARMA L.P. (US) | 2015-07-21 | — | — | US | disclosed |
| US-20150141643-A1 | SUBSTITUTED-QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA L.P. | 2015-05-21 | — | — | US | disclosed |
| US-20150011529-A1 | AZETIDINE-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | PURDUE PHARMA L.P. | 2015-01-08 | — | — | US | disclosed |
| US-20140128346-A1 | PHOSPHORUS-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | PURDUE PHARMA L.P. (US) | 2014-05-08 | — | — | US | disclosed |
| US-20140045830-A1 | CYCLIC UREA- OR LACTAM-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | SHIONOGI & CO., LTD. (JP) | 2014-02-13 | — | — | US | disclosed |
| US-20120174324-A1 | DYES FOR POLYMER COLORATION, THEIR PREPARATION AND THEIR USE | DYSTAR COLOURS DEUTSCHLAND GMBH (DE) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159785-A1 | SUBSTITUTED-QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND THE USES THEREOF | P2RX4, P2RX5, P2RX3 | PER2 3434/4885CRY1 3360/4885CRY2 2859/4885 |
| US-20150011529-A1 | AZETIDINE-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | QDPR, P2RX5, P2RX1 | PER2 3335/4885CRY1 2253/4885CRY2 2777/4885 |
| US-20140045830-A1 | CYCLIC UREA- OR LACTAM-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | QPCT, UBXN1, NQO2 | PER2 2114/4885CRY1 871/4885CRY2 1784/4885 |
| US-20150141643-A1 | SUBSTITUTED-QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND THE USES THEREOF | P2RX4, P2RX5, P2RX3 | PER2 3434/4885CRY1 3360/4885CRY2 2859/4885 |
| US-20140128346-A1 | PHOSPHORUS-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | P2RX4, P2RX1, P2RX5 | PER2 3411/4885CRY1 1271/4885CRY2 1896/4885 |
| US-20120174324-A1 | DYES FOR POLYMER COLORATION, THEIR PREPARATION AND THEIR USE | IK, H1-0, H1-5 | PER2 2805/4885CRY1 138/4885CRY2 232/4885 |
| US-20150315201-A1 | INDOLE AND INDOLINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | IDO1, IDO2, TPH2 | PER2 2307/4885CRY1 2954/4885CRY2 1543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.